DOCSLIB.ORG

IEIH Ishares Evolved US Innovative Healthcare ETF Gray Swan Event

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IEIH Ishares Evolved US Innovative Healthcare ETF Gray Swan Event ETF Risk Report: IEIH Buyer beware: Every ETF holds the full risk of its underlying equities Disclosures in the best interest of investors iShares Evolved U.S. Innovative Healthcare ETF Gray Swan Event Risks exist for every equity held by IEIH. Gray swan events include accounting fraud, management failures, failed internal controls, M&A problems, restatements, etc. These risks occur infrequently, but Gray Swan Event Factor for IEIH 2.31% consistently for all equities. Equities account for 99.25% of IEIH’s assets. Most investors ignore these risks until after they are disclosed; whereupon a stock’s price drops precipitously. Just as insurance companies can predict likely costs for a driver’s future car accidents based on the driver’s history, Watchdog Research contacts each ETF asking how they notify investors about we predict the likely cost (price drop) for IEIH following accounting governance risks in equities in their fund. We will publish their response gray swan disclosures within its holdings. The expected when received. price decrease across the IEIH equity portfolio is 2.31%. However, individual equity risks vary signicantly. This report helps investors know their risk exposure. Inception Date: 03/21/2020 Year-to-Date Return: 0.27% The iShares Evolved U.S. Innovative Healthcare ETF seeks to provide to access to U.S. companies with innovative Net Assets: $35.5m 1-Year Return: 31.44% healthcare exposure, such as pharmaceutical and biotechnology companies. The Fund is an actively Price: $32.34 3-Year Return: 13.69% managed exchange-traded fund and does not seek to Net Asset Value (NAV): $32.25 5-Year Return: NA replicate the performance of a specied index. Sector funds are by denition non-diversied. Net Expense Ratio: 0.18% Yield: 2.85% As of: 03/31/2021 Company Ticker Held Current GSEF Category Value Top Holdings by Value Johnson & Johnson JNJ Long 2.34% Mid $3.62m This table shows Gray Swan Event Factors for the top ten equity holdings by dollar-value, as of Sep 24, 2021. Pzer Inc. PFE Long 3.27% Mid $2.25m Investors should invest in ETFs only when they adequately Merck & Co., Inc. MRK Long 3.34% Mid $2.21m understand an ETF’s risks. Buyer beware. ETF prospectuses generally acknowledge that ETF managers Eli Lilly And Company LLY Long 2.99% Mid $2.21m do NO traditional risk analysis on equities in their fund. Abbvie Inc. ABBV Long 0.92% Low $2.19m Our Gray Swan Event Factors are meant to inform investors of signicant traditional accounting and Moderna, Inc. MRNA Long 1.27% Low $2.02m managerial risks for the equities in each ETF. Bristol Myers Squib... BMY Long 2.24% Mid $1.79m ETF Risk Reports are published quarterly on dedicated Gilead Sciences Inc. GILD Long 2.15% Mid $1.7m platforms like Factset, Renitiv, Capital IQ etc. Weekly updates are available for a paid subscription. Amgen Inc. AMGN Long 2.07% Mid $1.59m For more details contact: [email protected] Regeneron Pharmaceu... REGN Long 2.30% Mid $1.35m Company Ticker Held Current GSEF Category Value Riskiest Holdings Athenex, Inc. ATNX Long 12.82% Extreme $8.24k This table shows the individual Gray Swan Event Factors for this ETF’s most at-risk equities as of Sep 24, 2021. Ani Pharmaceuticals... ANIP Long 12.51% Extreme $5.4k The average equity GSEF across 6,500 public equities is Fibrogen Inc. FGEN Long 10.56% Extreme $53.9k 1.25%. Equities with a GSEF between 5% and 10% are considered high risk. Equities with a GSEF above 10% are Beam Therapeutics Inc. BEAM Long 7.02% High $73.5k extreme risks. Gray Swan Event Factors are derived from skilled analysts Myriad Genetics Inc. MYGN Long 6.47% High $23.5k charting 15 years of negative gray swan event disclosures Sorrento Therapeuti... SRNE Long 6.31% High $54.8k against stock price declines following such disclosures. A Gray Swan Event Factor is an assessment of the Intercept Pharmaceu... ICPT Long 6.10% High $14.9k likelihood of, and 12-month price risk for, gray swan Jazz Pharmaceutical... JAZZ Long 6.04% High $263k events for each equity. Icu Medical Inc. ICUI Long 6.02% High $22.6k Replimune Group, Inc. REPL Long 5.91% High $24.7k Watchdog Research, Inc. • www.watchdogresearch.com • [email protected] • (855) 820-6272 This table lists the equity holdings for iShares Evolved U.S. Innovative Healthcare ETF ranked by highest GSE Factor (riskiest rst). We list all equities (US and foreign) for this ETF. However, some foreign listings only show via a ticker. To further evaluate risks, you can access details for each company by opening its Brief Watchdog Report available for viewing and pdf download. The report is free to readers for their personal consumption and it includes the executive summary data pulled from the full Watchdog Report. To learn more about the full Watchdog and GSEF Reports go to last page or visit watchdogresearch.com. Company Access Details Ticker Held Current GSEF Category Value Athenex, Inc. Watchdogresearch.com/watchdog/$ATNX ATNX Long 12.82% Extreme $8.24k Ani Pharmaceuticals Inc. Watchdogresearch.com/watchdog/$ANIP ANIP Long 12.51% Extreme $5.4k Fibrogen Inc. Watchdogresearch.com/watchdog/$FGEN FGEN Long 10.56% Extreme $53.9k Beam Therapeutics Inc. Watchdogresearch.com/watchdog/$BEAM BEAM Long 7.02% High $73.5k Myriad Genetics Inc. Watchdogresearch.com/watchdog/$MYGN MYGN Long 6.47% High $23.5k Sorrento Therapeutics, Inc. Watchdogresearch.com/watchdog/$SRNE SRNE Long 6.31% High $54.8k Intercept Pharmaceuticals Inc. Watchdogresearch.com/watchdog/$ICPT ICPT Long 6.10% High $14.9k Jazz Pharmaceuticals Plc. Watchdogresearch.com/watchdog/$JAZZ JAZZ Long 6.04% High $263k Icu Medical Inc. Watchdogresearch.com/watchdog/$ICUI ICUI Long 6.02% High $22.6k Replimune Group, Inc. Watchdogresearch.com/watchdog/$REPL REPL Long 5.91% High $24.7k Vaxart, Inc. Watchdogresearch.com/watchdog/$VXRT VXRT Long 5.90% High $13.1k Ziopharm Oncology Inc. Watchdogresearch.com/watchdog/$ZIOP ZIOP Long 5.87% High $8.83k Baxter International Inc. Watchdogresearch.com/watchdog/$BAX BAX Long 4.92% Mid $168k Supernus Pharmaceuticals, Inc. Watchdogresearch.com/watchdog/$SUPN SUPN Long 4.76% Mid $37.3k Akebia Therapeutics, Inc. Watchdogresearch.com/watchdog/$AKBA AKBA Long 4.74% Mid $17.1k Endo International Plc. Watchdogresearch.com/watchdog/$ENDP ENDP Long 4.64% Mid $15.4k Voyager Therapeutics, Inc. Watchdogresearch.com/watchdog/$VYGR VYGR Long 4.62% Mid $2.91k Bluebird Bio, Inc. Watchdogresearch.com/watchdog/$BLUE BLUE Long 4.35% Mid $70.2k Horizon Pharma Plc. Watchdogresearch.com/watchdog/$HZNP HZNP Long 4.34% Mid $474k Frequency Therapeutics, Inc. Watchdogresearch.com/watchdog/$FREQ FREQ Long 4.16% Mid $7.27k Acadia Pharmaceuticals Inc. Watchdogresearch.com/watchdog/$ACAD ACAD Long 4.06% Mid $74k Caredx, Inc. Watchdogresearch.com/watchdog/$CDNA CDNA Long 3.96% Mid $34.4k Amneal Pharmaceuticals, Inc. Watchdogresearch.com/watchdog/$AMRX AMRX Long 3.90% Mid $15.1k Alkermes Plc. Watchdogresearch.com/watchdog/$ALKS ALKS Long 3.89% Mid $90.7k Novavax Inc. Watchdogresearch.com/watchdog/$NVAX NVAX Long 3.86% Mid $284k Epizyme, Inc. Watchdogresearch.com/watchdog/$EPZM EPZM Long 3.77% Mid $17.4k Tricida, Inc. Watchdogresearch.com/watchdog/$TCDA TCDA Long 3.76% Mid $3.04k Provention Bio, Inc. Watchdogresearch.com/watchdog/$PRVB PRVB Long 3.74% Mid $9.41k Ironwood Pharmaceuticals Inc. Watchdogresearch.com/watchdog/$IRWD IRWD Long 3.72% Mid $42.5k Ardelyx, Inc. Watchdogresearch.com/watchdog/$ARDX ARDX Long 3.72% Mid $14.3k Nextcure, Inc. Watchdogresearch.com/watchdog/$NXTC NXTC Long 3.72% Mid $2.99k Spectrum Pharmaceuticals Inc. Watchdogresearch.com/watchdog/$SPPI SPPI Long 3.68% Mid $9.21k Ligand Pharmaceuticals Inc. Watchdogresearch.com/watchdog/$LGND LGND Long 3.59% Mid $60.6k Charles River Laboratories International Watchdogresearch.com/watchdog/$CRL CRL Long 3.58% Mid $171k Inc. Chinook Therapeutics, Inc. Watchdogresearch.com/watchdog/$KDNY KDNY Long 3.57% Mid $2.84k Catalent, Inc. Watchdogresearch.com/watchdog/$CTLT CTLT Long 3.42% Mid $171k Watchdog Research, Inc. • www.watchdogresearch.com • [email protected] • (855) 820-6272 Company Access Details Ticker Held Current GSEF Category Value Kadmon Holdings, Inc. Watchdogresearch.com/watchdog/$KDMN KDMN Long 3.40% Mid $19k Merck & Co., Inc. Watchdogresearch.com/watchdog/$MRK MRK Long 3.34% Mid $2.21m Chemocentryx, Inc. Watchdogresearch.com/watchdog/$CCXI CCXI Long 3.34% Mid $15.3k Pzer Inc. Watchdogresearch.com/watchdog/$PFE PFE Long 3.27% Mid $2.25m Adverum Biotechnologies, Inc. Watchdogresearch.com/watchdog/$ADVM ADVM Long 3.27% Mid $5.85k Sarepta Therapeutics, Inc. Watchdogresearch.com/watchdog/$SRPT SRPT Long 3.23% Mid $147k Bausch Health Companies Inc. Watchdogresearch.com/watchdog/$BHC BHC Long 3.22% Mid $143k Allakos, Inc. Watchdogresearch.com/watchdog/$ALLK ALLK Long 3.14% Mid $63.8k La Jolla Pharmaceutical Co. Watchdogresearch.com/watchdog/$LJPC LJPC Long 3.13% Mid $2.17k Biogen Inc. Watchdogresearch.com/watchdog/$BIIB BIIB Long 3.04% Mid $1.12m Ionis Pharmaceuticals Inc. Watchdogresearch.com/watchdog/$IONS IONS Long 3.02% Mid $146k Eli Lilly And Company Watchdogresearch.com/watchdog/$LLY LLY Long 2.99% Mid $2.21m Medicinova Inc. Watchdogresearch.com/watchdog/$MNOV MNOV Long 2.97% Mid $3.83k Y Mabs Therapeutics, Inc. Watchdogresearch.com/watchdog/$YMAB YMAB Long 2.97% Mid $21.6k Karyopharm Therapeutics Inc. Watchdogresearch.com/watchdog/$KPTI KPTI Long 2.94% Mid $21.3k Gossamer Bio, Inc. Watchdogresearch.com/watchdog/$GOSS GOSS Long 2.94% Mid $11.4k United Therapeutics Corp. Watchdogresearch.com/watchdog/$UTHR UTHR Long 2.93% Mid $186k Collegium Pharmaceutical, Inc. Watchdogresearch.com/watchdog/$COLL COLL Long 2.90% Mid $14k Dynavax Technologies Corp. Watchdogresearch.com/watchdog/$DVAX DVAX Long 2.78% Mid $13.9k Editas Medicine, Inc.
Load more

Recommended publications
  • United States Court of Appeals for The
    Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page1 of 37 14‐4353‐cv Apotex Inc., et al., v. Acorda Therapeutics, Inc. UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT August Term, 2015 (Argued: November 12, 2015 Decided: May 16, 2016) Docket No. 14‐4353‐cv ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x APOTEX INC., et al., Plaintiffs‐Appellants, ‐ v.‐ ACORDA THERAPEUTICS, INC., Defendant‐Appellee. ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x Before: JACOBS, LIVINGSTON and DRONEY, Circuit Judges. This appeal concerns two distinct questions: the circumstances under which the filing of a citizen petition with the Food and Drug Administration provides grounds for an antitrust claim, and the scope of false advertising Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page2 of 37 liability under the Lanham Act. Plaintiffs Apotex Incorporated and Apotex Corporation appeal from the judgment of the United States District Court for the Southern District of New York (Swain, J.) that granted defendant Acorda Therapeutics, Inc.’s motion to dismiss plaintiffs’ Sherman Act claim and that granted summary judgment in favor of defendant on the Lanham Act claims (Torres, J.). Because each of these conclusions was sound, we affirm. KEITH D. PARR (with Joseph N. Froehlich, Scott B. Feder, Hugh S. Balsam, James T. Peterka, and Andy J. Miller on the brief), Locke Lord LLP, Chicago, Illinois, for Appellants Apotex Incorporated & Apotex Corporation. JOHN W. NIELDS, JR. (with Jason C. Raofield and Colin P. Watson on the brief), Covington & Burling LLP, Washington, D.C. for Appellee Acorda Therapeutics, Inc. DENNIS JACOBS, Circuit Judge: The parties are rival manufacturers of tizanidine, a drug for treating spasticity.
    [Show full text]
  • March 31, 2021
    Units Cost Market Value US Equity Index Fund US Equities 95.82% Domestic Common Stocks 10X GENOMICS INC 126 10,868 24,673 1LIFE HEALTHCARE INC 145 6,151 4,794 2U INC 101 5,298 4,209 3D SYSTEMS CORP 230 5,461 9,193 3M CO 1,076 182,991 213,726 8X8 INC 156 2,204 4,331 A O SMITH CORP 401 17,703 28,896 A10 NETWORKS INC 58 350 653 AAON INC 82 3,107 5,132 AARON'S CO INC/THE 43 636 1,376 ABBOTT LABORATORIES 3,285 156,764 380,830 ABBVIE INC 3,463 250,453 390,072 ABERCROMBIE & FITCH CO 88 2,520 4,086 ABIOMED INC 81 6,829 25,281 ABM INDUSTRIES INC 90 2,579 3,992 ACACIA RESEARCH CORP 105 1,779 710 ACADIA HEALTHCARE CO INC 158 8,583 9,915 ACADIA PHARMACEUTICALS INC 194 6,132 4,732 ACADIA REALTY TRUST 47 1,418 1,032 ACCELERATE DIAGNOSTICS INC 80 1,788 645 ACCELERON PHARMA INC 70 2,571 8,784 ACCO BRANDS CORP 187 1,685 1,614 ACCURAY INC 64 483 289 ACI WORLDWIDE INC 166 3,338 6,165 ACTIVISION BLIZZARD INC 1,394 52,457 133,043 ACUITY BRANDS INC 77 13,124 14,401 ACUSHNET HOLDINGS CORP 130 2,487 6,422 ADAPTHEALTH CORP 394 14,628 10,800 ADAPTIVE BIOTECHNOLOGIES CORP 245 11,342 10,011 ADOBE INC 891 82,407 521,805 ADT INC 117 716 1,262 ADTALEM GLOBAL EDUCATION INC 99 4,475 3,528 ADTRAN INC 102 2,202 2,106 ADVANCE AUTO PARTS INC 36 6,442 7,385 ADVANCED DRAINAGE SYSTEMS INC 116 3,153 13,522 ADVANCED ENERGY INDUSTRIES INC 64 1,704 7,213 ADVANCED MICRO DEVICES INC 2,228 43,435 209,276 ADVERUM BIOTECHNOLOGIES INC 439 8,321 1,537 AECOM 283 12,113 17,920 AERIE PHARMACEUTICALS INC 78 2,709 1,249 AERSALE CORP 2,551 30,599 31,785 AES CORP/THE 1,294 17,534 33,735 AFFILIATED
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • ENDO INTERNATIONAL PLC (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): January 16, 2015 ENDO INTERNATIONAL PLC (Exact name of registrant as specified in its charter) Ireland 001-36326 Not Applicable (State or other jurisdiction of (Commission (I.R.S Employer incorporation or organization) File Number) Identification No.) Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland Not Applicable (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code 011-353-1-268-2000 Not Applicable Former name or former address, if changed since last report Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01 Other Events. This Current Report on Form 8-K is being filed pursuant to a memorandum of understanding regarding the settlement of certain litigation relating to the proposed merger (the “Merger”) between Auxilium Pharmaceuticals, Inc. (“Auxilium”) and Avalon Merger Sub Inc. (“Merger Sub”) pursuant to that certain Amended and Restated Agreement and Plan of Merger, dated as of November 17, 2014 (the “Merger Agreement”), by and among Auxilium, Endo International plc (“Endo”), Endo U.S.
    [Show full text]
  • Companies in Attendance
    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
    [Show full text]
  • US Pharma's Business Model
    INNOVATION-FUELLED, SUSTAINABLE, INCLUSIVE GROWTH Working Paper US Pharma’s Business Model: Why It Is Broken, and How It Can Be Fixed William Lazonick Matt Hopkins Ken Jacobson Mustafa Erdem Sakinç Öner Tulum The Academic-Industry Research Network 13/2017 May This project has received funding from the European Union Horizon 2020 Research and Innovation action under grant agreement No 649186 US Pharma’s Business Model: Why It Is Broken, and How It Can Be Fixed William Lazonick Matt Hopkins Ken Jacobson Mustafa Erdem Sakinç Öner Tulum The Academic-Industry Research Network (www.theAIRnet.org) Revised, May 22, 2017 Chapter for inclusion in David Tyfield, Rebecca Lave, Samuel Randalls, and Charles Thorpe, eds., The Routledge Handbook of the Political Economy of Science The contents of this chapter are drawn from two contributions by the Academic- Industry Research Network to the United Nations Secretary-General’s High-Level Panel on Access to Medicines: http://www.unsgaccessmeds.org/list-of-contribution/ William Lazonick is Professor of Economics, University of Massachusetts Lowell; Visiting Professor, University of Ljubljana; Professeur Associé, Institut Mines- Télécom; and President, The Academic-Industry Research Network (theAIRnet); Matt Hopkins, Ken Jacobson, Mustafa Erdem Sakinç, and Öner Tulum are researchers at theAIRnet. Jacobson is also theAIRnet communications director. Sakinç has just completed a PhD in economics at the University of Bordeaux. Tulum is a PhD student at the University of Ljubljana. Funding for this research came from the Institute for New Economic Thinking (Collective and Cumulative Careers project), the European Union Horizon 2020 Research and Innovation Programme under grant agreement No.
    [Show full text]
  • The Top 15 Generic Drugmakers of 2016 by Eric Sagonowsky, Eric Palmer, Angus Liu
    The top 15 generic drugmakers of 2016 by Eric Sagonowsky, Eric Palmer, Angus Liu Branded drugmakers weren’t the only ones working through a tumultuous 2016. Generics companies faced pricing pressure, too. And while branded companies suffer pricing pain on costly cutting-edge therapies, generics outfits feel the pinch with already-thin margins, making pressure all the more agonizing. How is the industry responding? By consolidating and hoping to save money, for one. Take a look at FiercePharma’s 2014 ranking, and it’s clear that some companies have made leaps too big to depend on organic growth alone. Take Teva, which topped the 2016 list as it did in 2014. It wrapped up the biggest M&A move in recent history for the generics industry, swallowing Allergan’s unbranded offerings for $40.5 billion in August. The massive move will continue to reverberate in the generics industry for years to come. Top drugmakers by 2016 generics revenue in USD billions Teva Pharmaceutical Industries 9.85 Mylan 9.43 Novartis 9 Pfizer 4.57 Allergan 4.5 Sun Pharmaceutical Industries 3.61 Fresenius 2.8 Endo International 2.57 Lupin 2.49 Sanofi 2.05 Aspen Pharmacare 2 Aurobindo Pharma 1.86 Dr. Reddy's Laboratories 1.78 Cipla 1.61 Apotex 1.6 Source: Evaluate, May 2017 Get the data Sales data for Sun Pharma, Fresenius, Lupin, Aspen Pharmacare, Aurobindo, Cipla, and Apotex are Evaluate estimates. Dr. Reddy’s data provided from company filing. Behind Teva came Mylan, which also completed a big deal last year, a $7.2 billion buyout of Sweden’s Meda.
    [Show full text]
  • Based on Our Discussion with Radford, Management Identified Our Peer Companies to Include the Following 19 Biotechnology and Pharmaceutical Companies for 2015
    Based on our discussion with Radford, management identified our peer companies to include the following 19 biotechnology and pharmaceutical companies for 2015: Ariad Pharmaceuticals Inc. Infinity Pharmaceuticals, Inc. Progenics Pharmaceuticals, Inc. Array BiopPharma, Inc. Lexicon Pharmaceuticals, Inc Repligen Corporation Celldex Therapeutics, Inc. MacroGenics, Inc. Spectrum Pharmaceuticals, Inc. CTI BioPharma Corp. Merrimack Pharmaceuticals, Inc. Synta Pharmaceuticals Corp. DepoMed Inc. NewLink Genetics Corporation XOMA Corporation Halozyme Therpeutics, Inc. OncoMed Pharmaceuticals, Inc. Immunomedics Inc. Peregrine Pharmaceuticals, Inc These peer companies were selected from among publicly-held U.S. pharmaceutical and biotechnology companies with comparable operations in mid– to late–stages of product development or small commercial products in the U.S. based on the following criteria: number and stage of development programs; number of employees; market capitalization; and number of and revenue from commercial products. The market data included information as to base salaries, cash bonuses and stock option awards. Use of Compensation Consultants Our Compensation Committee is authorized to retain its own independent advisors to assist in carrying out its responsibilities. Our Compensation Committee engaged Radford to analyze historic compensation and establish recommendations for executive compensation for 2015 and methodologies for determining compensation on an on-going basis. Benchmarking in the Context of Our Other Executive Compensation Principles Our Compensation Committee and our Board of Directors use market data as one means of evaluating and establishing executive pay. In instances where an executive officer is believed to be especially suited to our company or important to our success, the Compensation Committee may establish or recommend compensation that deviates from industry averages or other specific benchmarks.
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • Fidelity® Nasdaq Composite Index® Fund
    Fidelity® Nasdaq Composite Index® Fund Semi-Annual Report May 31, 2021 Contents Note to Shareholders 3 Investment Summary 4 Schedule of Investments 6 Financial Statements 85 Notes to Financial 89 Statements Shareholder Expense 97 Example Board Approval of 98 Investment Advisory Contracts and Management Fees Liquidity Risk 106 Management Program To view a fund’s proxy voting guidelines and proxy voting record for the 12-month period ended June 30, visit http://www.fidelity.com/proxyvotingresults or visit the Securities and Exchange Commission’s (SEC) web site at http://www.sec.gov. You may also call 1-800-544-8544 to request a free copy of the proxy voting guidelines. Nasdaq®, OMX®, NASDAQ OMX®, Nasdaq Composite®, and The Nasdaq Stock Market®, Inc. are registered trademarks of The NASDAQ OMXGroup, Inc. (which with its Affiliates are the Corporations) and are licensed for use by Fidelity. The product has not been passed on by the Corporations as to its legality or suitability. The product is not issued, endorsed or sold by the Corporations. The Corporations make no warranties and bear no liability with respect to shares of the product. Standard & Poor’s, S&P and S&P 500 are registered service marks of The McGraw-Hill Companies, Inc. and have been licensed for use by Fidelity Distributors Corporation. Other third-party marks appearing herein are the property of their respective owners. All other marks appearing herein are registered or unregistered trademarks or service marks of FMR LLC or an affiliated company. © 2021 FMR LLC. All rights reserved. This report and the financial statements contained herein are submitted for the general information of the shareholders of the Fund.
    [Show full text]
  • Tuesday, November 29 Track One Villard, 2Nd Floor Track Two
    Tuesday, Track One Track Two Track Three Track Four Track Five Track Six Track Seven November 29 Villard, 2nd Floor Spellman, 5th Floor Holmes 1, 4th Floor Holmes 2, 4th Floor Hubbard 1, 5th Floor Kennedy 1, 4th Floor Kennedy 2, 4th Floor Public & Private Track Private Track Registration - Villard Foyer, 2nd Floor 7:30 Continental Breakfast - Reid Salon, 2nd Floor 7:30 DentalPlans.com, Inc. SYMIC BIO, INC. Luminex Corporation Insmed Incorporated AngioDynamics Inc. Vascular Biogenics Ltd. 7:30-7:55 ConforMIS, Inc. (CFMS) (LMNX) (INSM) (ANGO) (VBLT) 7:50 OticPharma, Ltd. Accera, Inc. Gilead Sciences, Inc. Medidata Solutions, Inc. Horizon Pharma plc NxStage Medical, Inc. Acorda Therapeutics, UDG Healthcare plc 8:00-8:25 8:10 Availity, LLC (GILD) (MDSO) (HZNP) (NXTM) Inc. (ACOR) (UDG LN) MiMedx Group, Inc. 8:30 VisionGate, Inc. Boston Scientific Masimo Corporation COMPANY TO BE (MDXG) 8:30-8:55 Akorn, Inc. (AKRX) Teladoc, Inc. (TDOC) Corporation (BSX) (MASI) ANNOUNCED (JS) Anika Therapeutics Inc. 8:50 Benvenue Medical, Inc. (ANIK) Supernus Zimmer Biomet Henry Schein, Inc. Benefitfocus, Inc. Stealth BioTherapeutics 9:00-9:25 Pharmaceuticals, Inc. Ignyta, Inc. (RXDX) 9:10 EarLens Corporation Holdings, Inc. (ZBH) (HSIC) (BNFT) Incorporated (SUPN) Schedule for Tuesday, November 29, 2016 - Page 1 of 10 Schedule as of November 18, 2016. Schedule is subject to change. Tuesday, Track One Track Two Track Three Track Four Track Five Track Six Track Seven November 29 Villard, 2nd Floor Spellman, 5th Floor Holmes 1, 4th Floor Holmes 2, 4th Floor Hubbard 1, 5th Floor Kennedy 1, 4th Floor Kennedy 2, 4th Floor ProMetic Life Sciences Adamas 9:30 Graybug Vision, Inc.
    [Show full text]